StockNews.AISignal intelligence
Illumina, Inc. · NASDAQ · Healthcare
Browse public ILMN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Illumina (ILMN) benefits from CMS reimbursement of $2,989.55 for its TruSight Oncology test, expected to boost genomic profiling adoption. This positive momentum aligns with analysts projecting earnings growth, indicating potential upside as the company prepares for its next earnings report on February 5, 2026.
View signal analysisIllumina launched a new dataset linking genetic changes for AI-driven drug discovery.
View signal analysisILMN reports Q3 earnings of $1.34, exceeding consensus expectations of $1.17. Revenue of $1.084 billion beats forecasts, showing strong clinical market performance. Fiscal 2025 earnings guidance raised to $4.65-$4.75 per share, above consensus. New operating margin estimates increased to between 22.75% and 23% for 2025. Evercore ISI raises ILMN price target from $132 to $142, maintaining Outperform rating.
View signal analysisIllumina's stock dropped 11% in a week amid strong competition. MGI Tech secures market share despite U.S. sanctions impacting sales. IQVIA shows stronger growth and profitability compared to Illumina. ILMN's quarterly revenue growth is -4.8%, below IQV's 5.3%. Trefis portfolio reports superior returns, indicating strong investment strategies.
View signal analysis